Compare Amgen, Inc. (AMGN) vs Omnicom Group Inc. (OMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Omnicom Group Inc. — how do they compare? Amgen, Inc. trades at $414.68 (market cap $224.14B), while Omnicom Group Inc. trades at $84.23 (market cap $23.58B). The key difference: Amgen, Inc. is far larger — about 9.5× Omnicom Group Inc.'s market cap, and Omnicom Group Inc. pays the higher dividend (3.72%). Which is the better fit depends on your goals.
| AMGN | OMC | |
|---|---|---|
Market Cap | $224.14B | $23.58B |
Sector | Health | Media |
52-Week High | $417.20 | $86.22 |
52-Week Low | $271.18 | $67.27 |
Enterprise Value | $267.45B | $31.66B |
Dividend Yield | 2.43% | 3.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $417.20, up 1.52% with strong technical momentum as price approaches resistance near $421. The company demonstrates robust fundamentals with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, marking the third consecutive quarterly beat. Revenue growth continues with 2025 revenue reaching $36.75 billion and 2026 projected at $38.1 billion, supported by strong performance from key products like Tezspire and Repatha.
Amgen presents a compelling growth story with raised 2026 guidance and strong product pipeline, though elevated valuation ratios (P/E 25.73, P/S 5.91) and high debt levels ($56.55 billion long-term debt) warrant caution. Analyst consensus remains bullish with 59% buy ratings and $394.69 price target, but current price trades above consensus target, suggesting near-term consolidation potential.
Omnicom Group (OMC) trades at $84.65, down 0.69% on the day, with a bullish technical outlook per moving averages but mixed oscillators. Recent Q2 2026 earnings beat expectations with $2.65 EPS, driven by 6.1% organic revenue growth and margin expansion post-Interpublic acquisition. The company maintains a 4% dividend yield and active buybacks, though high P/E of 232.3 reflects net income volatility.
Outlook is positive with analyst consensus target of $107.00 (27% upside), but risks include integration costs, debt increase, and competitive pressures. The stock offers value from synergy realization and AI-driven growth initiatives, yet investors must monitor execution on cost savings and organic growth sustainability amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →
